DaVita Inc. (a shortened contraction of "dare vita, meaning "to give life" in the Italian language), incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients (36% of the total of 557,000 patients in the U.S.), and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DVA | DAVITA INC. | 2026-05-22 14:59:46 | 198.47 | -0.31 | -0.16 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVA | 0000927066 | DAVITA INC. | US23918K1088 | M2XHYMU3TZNEZURC6H66 | 510354549 | NYSE | 8090 | Services-Misc Health & Allied Services, NEC | 1231 | DE | 2000 16TH STREET | DENVER | CO | 80202 | UNITED STATES | US | 310-536-2668 | 2000 16TH STREET, DENVER, CO, 80202 | 2000 16TH STREET, DENVER, CO, 80202 | DAVITA HEALTHCARE PARTNERS INC. | Healthcare | 1992 | Javier J. Rodriguez | 78,000 | https://davita.com | 10,600,000,000 | 69,190,000 | 64,200,000 | DaVita Inc. (a shortened contraction of "dare vita, meaning "to give life" in the Italian language), incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients (36% of the total of 557,000 patients in the U.S.), and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. | 2026-05-21 15:52:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 10,600,000,000 | -1,200,000,000 | -10.1695 | 66,800,000 | -13,200,000 | -16.5 |
| 2024 | 11,800,000,000 | 2,600,000,000 | 28.2609 | 80,000,000 | -7,700,000 | -8.7799 |
| 2023 | 9,200,000,000 | 1,800,000,000 | 24.3243 | 87,700,000 | -2,700,000 | -2.9867 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| David P. Maughan | Chief Operating Officer | 2025 | 725,000 | 0 | 3,178,454 | 686,330 | 252,474 | 5,592,259 |
| James O. Hearty | Chief Compliance Officer | 2025 | 600,000 | 0 | 720,420 | 455,331 | 16,352 | 1,962,115 |
| Javier J. Rodriguez | Chief Executive Officer | 2025 | 1,500,000 | 0 | 11,442,481 | 2,089,491 | 478,643 | 18,210,597 |
| Joel Ackerman | Treasurer, Chief Financial Officer | 2025 | 834,616 | 0 | 3,644,589 | 774,063 | 16,686 | 6,129,962 |
| Javier J. Rodriguez | Chief Executive Officer | 2024 | 1,500,000 | 0 | 15,849,833 | 4,118,119 | 339,537 | 21,807,489 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 13,643,069,000 | 12,815,550,000 | 12,140,147,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 13,643,069,000 | 12,815,550,000 | 12,140,147,000 |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 1,673,630,000 | 1,538,341,000 | 1,473,984,000 |
| Operating Expenses | 11,599,454,000 | 10,725,067,000 | 10,537,363,000 |
| Operating Income | 2,043,615,000 | 2,090,483,000 | 1,602,784,000 |
| Net Income | 746,803,000 | 936,342,000 | 691,535,000 |
| Earnings Per Share Basic | 10.06 | 11.02 | 7.62 |
| Earnings Per Share Diluted | 9.84 | 10.73 | 7.42 |
| Weighted Average Shares Outstanding Basic | 74,227,000 | 84,991,000 | 90,790,000 |
| Weighted Average Shares Outstanding Diluted | 75,885,000 | 87,274,000 | 93,182,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 676,438,000 | 794,933,000 | 380,063,000 |
| Marketable Securities Current | 24,303,000 | 51,064,000 | 11,610,000 |
| Accounts Receivable | 2,414,690,000 | 2,146,975,000 | 1,986,856,000 |
| Inventories | 160,627,000 | 134,559,000 | 143,105,000 |
| Non Trade Receivables | 494,414,000 | 383,166,000 | 422,669,000 |
| Other Assets Current | 156,285,000 | 122,948,000 | 102,645,000 |
| Total Assets Current | 4,058,003,000 | 3,746,072,000 | 3,137,906,000 |
| Marketable Securities Non Current | 40,966,000 | 33,660,000 | 47,890,000 |
| Property Plant And Equipment | 2,812,966,000 | 2,940,916,000 | 3,073,533,000 |
| Other Assets Non Current | 246,520,000 | 261,731,000 | 271,253,000 |
| Total Assets Non Current | 13,422,100,000 | 13,539,196,000 | 13,755,672,000 |
| Total Assets | 17,480,103,000 | 17,285,268,000 | 16,893,578,000 |
| Accounts Payable | 696,148,000 | 547,200,000 | 514,533,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 109,201,000 | 270,867,000 | 123,299,000 |
| Other Liabilities Current | 893,024,000 | 934,145,000 | 828,878,000 |
| Total Liabilities Current | 3,141,634,000 | 2,973,410,000 | 2,642,214,000 |
| Long Term Debt | 10,163,988,000 | 9,175,903,000 | 8,268,334,000 |
| Other Liabilities Non Current | 83,516,000 | 169,588,000 | 183,074,000 |
| Total Liabilities Non Current | 13,180,031,000 | 12,220,507,000 | 11,508,014,000 |
| Total Liabilities | 16,321,665,000 | 15,193,917,000 | 14,150,228,000 |
| Common Stock | 69,000 | 90,000 | 89,000 |
| Retained Earnings | -328,428,000 | 1,534,630,000 | 598,288,000 |
| Accumulated Other Comprehensive Income | -122,783,000 | -310,796,000 | -52,084,000 |
| Total Shareholders Equity | -651,082,000 | 121,122,000 | 1,056,097,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 715,348,000 | 723,860,000 | 745,443,000 |
| Share Based Compensation Expense | 139,953,000 | 102,788,000 | 112,375,000 |
| Other Non Cash Income Expense | 17,549,000 | -13,414,000 | 8,938,000 |
| Change In Accounts Receivable | 210,632,000 | 29,766,000 | -172,361,000 |
| Change In Inventories | 19,950,000 | -17,942,000 | 32,132,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 40,253,000 | 67,031,000 | 5,792,000 |
| Change In Accounts Payable | 128,303,000 | 1,699,000 | 26,890,000 |
| Change In Other Liabilities | -24,042,000 | 14,687,000 | 56,209,000 |
| Cash From Operating Activities | 1,886,500,000 | 2,022,038,000 | 2,059,031,000 |
| Purchases Of Marketable Securities | — | 0 | 0 |
| Sales Of Marketable Securities | 6,723,000 | 4,566,000 | 10,365,000 |
| Acquisition Of Property Plant And Equipment | 575,864,000 | 555,443,000 | 567,985,000 |
| Acquisition Of Business | 117,468,000 | 246,068,000 | — |
| Other Investing Activities | — | 0 | 0 |
| Cash From Investing Activities | -654,949,000 | -771,429,000 | -771,800,000 |
| Tax Withholding For Share Based Compensation | 35,291,000 | 134,040,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,000 | 1,000 | 2,000 |
| Repurchase Of Common Stock | 1,308,366,000 | 1,385,932,000 | 272,219,000 |
| Issuance Of Long Term Debt | 5,612,280,000 | 6,624,310,000 | 2,468,341,000 |
| Repayment Of Long Term Debt | 4,788,845,000 | 5,515,213,000 | 3,020,956,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -1,374,780,000 | -816,937,000 | -1,170,495,000 |
| Change In Cash | -122,078,000 | 415,191,000 | 125,645,000 |
| Cash At End Of Period | 676,438,000 | 794,933,000 | 380,063,000 |
| Income Taxes Paid | 176,688,000 | 387,940,000 | 268,091,000 |
| Interest Paid | 515,497,000 | 423,360,000 | 387,661,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 10.06 | 11.02 | 7.62 |
| Price To Earnings Ratio | 11.2932 | 13.5708 | 13.748 |
| Earnings Growth Rate | -8.7114 | 44.6194 | 26.3682 |
| Price Earnings To Growth Ratio | -1.2964 | 0.3041 | 0.5214 |
| Book Value Per Share | 15.6067 | 24.6067 | 30.2164 |
| Price To Book Ratio | 7.2796 | 6.0776 | 3.467 |
| Ebitda | 2,178,763,000 | 2,483,345,000 | 2,079,020,000 |
| Enterprise Value | 18,029,680,470 | 21,362,241,050 | 17,522,730,400 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -15.7786 | 77.9938 | 7.9459 |
| Capital Expenditures | 587,398,000 | 591,243,000 | 562,579,000 |
| Free Cash Flow | 1,299,102,000 | 1,430,795,000 | 1,496,452,000 |
| Return On Equity | -1.147 | 7.7306 | 0.6548 |
| One Year Beta | 0.476 | 0.4622 | 0.7541 |
| Three Year Beta | 0.5382 | 0.5206 | 0.5297 |
| Five Year Beta | 0.5073 | 0.6862 | 0.7183 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Hollar Jason M. | Director | 2026-05-15 | 250 | A | 6,605 |
| Schechter Adam H | Director | 2026-05-15 | 250 | A | 5,692 |
| DESOER BARBARA J | Director | 2026-05-15 | 250 | A | 250 |
| YALE PHYLLIS R | Director | 2026-05-15 | 250 | A | 14,563 |
| Arway Pamela M | Director | 2026-05-15 | 250 | A | 26,945 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Spouse | $1,001 - $15,000 |
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Self | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-01-12 | Sale (Full) | 2023-12-12 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2023-07-14 | Sale (Partial) | 2023-06-12 | Joint | $1,001 - $15,000 |
| Jerry Moran | Senator | 2022-01-21 | Sale (Partial) | 2021-12-21 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2025-10-07 | TX32 | Sale | 2025-09-25 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Western Wealth Management, LLC | 2026-03-31 | 59,939 | 390 | 153.6897 |
| Front Row Advisors LLC | 2026-03-31 | 9,990 | 65 | 153.6923 |
| Kentucky Retirement Systems | 2026-03-31 | 924,000 | 14,575 | 63.3962 |
| Edgestream Partners, L.P. | 2026-03-31 | 397,750 | 2,588 | 153.6901 |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 5,716,395 | 37,188 | 153.7161 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2026-03-31 | iShares Global Healthcare ETF | IXJ | 17,057 | 2,621,490.33 | 0.0723 |
| iSHARES TRUST | 2026-03-31 | iShares Russell 1000 Growth ETF | IWF | 141,627 | 21,766,653.63 | 0.0195 |
| iSHARES TRUST | 2026-03-31 | iShares U.S. Healthcare Providers ETF | IHF | 39,212 | 6,026,492.28 | 0.931 |
| iSHARES TRUST | 2026-03-31 | iShares Russell 1000 ETF | IWB | 25,074 | 3,853,623.06 | 0.009 |
| SCHWAB ANNUITY PORTFOLIOS | 2026-03-31 | Schwab S&P 500 Index Portfolio | SWP1Z | 1,873 | 287,861.37 | 0.0089 |